[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"obesity-abdominal\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:obesity-abdominal":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,5,0,[8,48,71,104,134],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":30,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":36,"lastUpdatePostDateStruct":37,"startDateStruct":40,"completionDateStruct":42,"leadSponsor":44,"locationsCount":47},"100584606","circadian-rhythms-in-human-adipose-100584606",false,"NCT06891534","Circadian Rhythms in Human Adipose","Circadian Regulation of Human Adipose Tissue Metabolism","Inclusion Criteria:\n\n* BMI 20-25 kg\u002Fm2 or 30-37 kg\u002Fm2\n* For participants with obesity a waist-to-hip ratio of ≥0.95 in males and ≥0.90 in females.\n* sedentary\n* females: non pregnant or breastfeeding\n* ability to provide written informed consent and follow study instructions\n\nExclusion Criteria:\n\n* History of mediations that impact adipocyte\u002Flipid metabolism\n* smoking\n* insomnia\n* sleep apnea\n* sleep medication use\n* employment in night or shift work\n* extreme chronotypes\n* Allergy to lidocaine",true,"ALL","18 Years","55 Years",{"count":21,"type":22},40,"ESTIMATED","INTERVENTIONAL",[25],"NA","The goal of this study is to understand the underlying circadian rhythms in subcutaneous adipose tissue of humans with our without continuous feeding and how these are altered in people who have obesity.",[28,29],"Obesity, Abdominal","Feeding Patterns",[31,32,33,34],"circadian rhythms","adipose tissue","obesity","feeding pattern","RECRUITING","2026-04-13",{"date":38,"type":39},"2026-04-14","ACTUAL",{"date":41,"type":39},"2021-07-01",{"date":43,"type":22},"2030-12",{"name":45,"class":46},"Mayo Clinic","OTHER",1,{"id":49,"slug":50,"hasResults":11,"nctId":51,"briefTitle":52,"officialTitle":52,"acronym":53,"eligibilityCriteria":54,"healthyVolunteers":16,"sex":17,"minAge":55,"maxAge":56,"enrollmentInfo":57,"targetDuration":4,"studyType":23,"phases":59,"briefSummary":60,"conditions":61,"keywords":4,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":62,"lastUpdatePostDateStruct":63,"startDateStruct":65,"completionDateStruct":67,"leadSponsor":69,"locationsCount":47},"100564337","nicotinamide-adenine-dinucleotide-nad-metabolism-in-human-brown-adipose-tissue-100564337","NCT06627868","Nicotinamide Adenine Dinucleotide (NAD+) Metabolism in Human Brown Adipose Tissue","BATNAD","Inclusion Criteria:\n\n* Willingness to provide informed consent to participate in the BATNAD study\n* Must be able to read and speak English\u002FFinnish\u002FSwedish well enough to completely understand the instructions and provide informed consent\n* Age 30-55 (sedentary lifestyle)\n* BMI = 18-25 kg\u002Fm2 (normal-weight subjects)\n* BMI ≥ 28 kg\u002Fm2 and waist circumference more than 100 cm in men and more than 90 cm in women (subjects with obesity)\n\nExclusion Criteria:\n\n* Inability to have PET\u002FCT (claustrophobia, metal implants, recent tattoo including metal components, weight \\> 200 kg)\n* Pregnancy and pregnancy related conditions (postpartum\u002Flactation during the last 12 months, or planning to become pregnant soon)\n* Major alterations in the menstrual cycle (e.g., amenorrhea)\n* Use of nicotine based products\n* Hypo- or hyper- thyroidism (medical history, TSH, T3 or T4 levels out of the normal range)\n* Diabetes mellitus (fasting Hb1Ac \\>6.5% or fasting glycaemia\\> 7.0 mmol\u002F)\n* Abnormal oral glucose tolerance test (2h OGTT \\> 11.1 mmol\u002FL)\n* Hypertension (blood pressure \\> 160\u002F100 mmHg)\n* Abnormal cardiovascular status (arrhythmia and\u002For long QTc in ECG, abnormal cardiac murmur, previous history of cardiovascular disease)\n* Abnormal coagulopathy (e.g., clotting abnormality)\n* Malignancies\n* Immunological, autoimmune and primary\u002Fsecondary immunodeficiency disorders (including or not any active treatment)\n* Virus or bacterial infection (both asymptomatic and symptomatic picture) within the 45 days prior to the study start\n* Vaccination within the 45 days prior to the study start\n* Episode of fever or major surgery, burns and traumas within the month prior to the study start\n* Chronic infections requiring chronic antibiotic or anti-viral treatment\n* Whole blood donation in the last 3 months (\\>400 mL of blood) or plans for blood donation during the entire protocol period\n* Weight change (intentional or not) over the last 6-months more than 5% of body weight, or plan to lose weight during the study\n* Allergy to lidocaine or epinephrine, or other local anaesthetics\n* Previous participation to studies where PET or CT method is used\n* Use of any medication that, in the opinion of local clinician\u002Fresearcher, would negatively impact or mitigate full participation and completion, or could influence the study results. This especially applies to the use of β or α adrenergic receptors agonists\u002Fantagonists (e.g., β-blockers).\n* Any other cardiovascular, pulmonary, orthopaedic, neurologic, psychiatric or other conditions that, in the opinion of the local clinician\u002Fresearcher, would preclude participation and successful completion of the protocol, or that would negatively impact or mitigate participation in and completion of the protocol","30 Years","65 Years",{"count":58,"type":22},68,[25],"A fully functional brown fat helps maintain a healthy weight and decreases the risk of metabolic diseases such as type II diabetes (T2DM). Unfortunately, in human adults, the functionality of brown fat declines with age, and it is one of the reasons for gaining unhealthy weight, particularly around the waistline (central obesity). Currently, scientists do not clearly understand the reasons for the decline in brown fat functionality. It is possible that the decline in the availability of the molecule Nicotinamide Adenine Dinucleotide (NAD+), which is central to several metabolic processes, plays a role in the decline in brown fat metabolism. This project will clarify whether NAD+-based molecular-targeted therapies for the enhancement of whole-body insulin sensitivity and brown fat metabolism will be successful in adult humans, which will eventually be an important target for reducing the development of obesity and its comorbidities such as T2DM.",[28],"2026-02-14",{"date":64,"type":39},"2026-02-18",{"date":66,"type":39},"2024-11-20",{"date":68,"type":22},"2027-08-31",{"name":70,"class":46},"University of Turku",{"id":72,"slug":73,"hasResults":11,"nctId":74,"briefTitle":75,"officialTitle":76,"acronym":4,"eligibilityCriteria":77,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":78,"targetDuration":4,"studyType":23,"phases":80,"briefSummary":81,"conditions":82,"keywords":87,"overallStatus":94,"whyStopped":4,"lastUpdateSubmitDate":95,"lastUpdatePostDateStruct":96,"startDateStruct":98,"completionDateStruct":100,"leadSponsor":102,"locationsCount":4},"100538192","cpap-in-patients-with-severe-obesity-after-anesthesia-100538192","NCT06287632","CPAP in Patients With Severe Obesity After Anesthesia","Assessment of Cardiopulmonary Function in Response to Continuous Positive Airway Pressure in Patients With Severe Obesity After Anesthesia","Inclusion Criteria:\n\n1. Adult patients (≥ 18 years old) scheduled for elective non-cardiothoracic surgery requiring general anesthesia with an endotracheal tube\n2. Planned admission to the post-anesthesia care unit (PACU) after surgery\n3. BMI ≥ 40 kg\u002Fm2\n4. At the time of baseline measurements in the PACU, patients meet the following criteria:\n\n   * Receiving ≤ 6 liters of supplemental nasal cannula oxygen\n   * Alert as defined by a Richmond Agitation Sedation Scale of 0 or -1\n   * Oriented to person, place, and time\n\nExclusion Criteria:\n\n1. Pregnancy, suspected pregnancy or less than six weeks postpartum Known or current pneumothorax\n2. Hemodynamic instability at the time of study assessment in the PACU defined as:\n\n   * systolic blood pressure \\\u003C90 mmHg or \\>180 mmHg\n   * mean blood pressure \\\u003C60 or \\>130 mmHg\n   * Any use of intravenous vasoactive agent\n   * heart rate \\\u003C 50 or \\> 120 beats per minute\n3. Respiratory insufficiency in PACU defined as:\n\n   * Respiratory rate \\> 30\n   * Oxygen saturation \\\u003C 92%\n   * Receiving \\> 6 liters of supplemental oxygen\n4. Known chronic lung disease requiring supplemental oxygen at home\n5. Known systolic heart dysfunction (left ventricular ejection fraction ≤ 30%)\n6. Contraindication for esophageal catheter placement:\n\n   * Known esophageal varices\n   * Known bacterial sinusitis\n   * Recent esophageal, nasopharyngeal, or laryngeal trauma or surgery\n   * Known coagulopathy: including history of thrombocytopenia defined as platelet count \\\u003C50,000; presence of hemophilia; known genetic disorder of coagulation (e.g.,deficits of protein C, protein S, von Willebrand factor) or oral and subcutaneous anticoagulation treatment (e.g., heparin, warfarin, and or other oral anticoagulants)\n7. Contraindication for electrical impedance tomograph belt placement:\n\n   * Pacemaker and\u002For internal cardiac defibrillator\n   * Chest skin injury\n8. Concern for study inclusion by the perioperative nurse or anesthesia team",{"count":79,"type":22},60,[25],"The goal of this study is to compare two continuous positive airway pressure (CPAP) settings on heart and lung function in patients with severe obesity after anesthesia. The main questions it aims to answer are:\n\n1. Does a recruitment maneuver and CPAP set to intrathoracic pressure (ITP) improve cardiopulmonary function compared to standard CPAP settings in patients with severe obesity after anesthesia?\n2. Does the location of adipose tissue influence the response to CPAP settings in patients with severe obesity after anesthesia?\n\nParticipants will undergo monitoring of their intrathoracic pressure using an esophageal catheter. In the recovery area after anesthesia, participants will receive two CPAP settings, each for 20 minutes.\n\n* Intervention 1: Recruitment maneuver and CPAP will set to the level of intrathoracic pressure\n* Intervention 2: CPAP set to home settings (if OSA is present) or between 8-10 cmH20 (if OSA is not present).",[28,83,84,85,86],"Anesthesia Morbidity","Apnea, Obstructive Sleep","Atelectases, Postoperative Pulmonary","Ventilator Lung",[88,89,90,91,92,93],"clinical trial","crossover studies","continuous positive airway pressure","electrical impedance tomography","esophageal pressure monitoring","transthoracic echocardiography","NOT_YET_RECRUITING","2025-11-17",{"date":97,"type":39},"2025-11-18",{"date":99,"type":22},"2026-06",{"date":101,"type":22},"2027-06",{"name":103,"class":46},"Massachusetts General Hospital",{"id":105,"slug":106,"hasResults":11,"nctId":107,"briefTitle":108,"officialTitle":109,"acronym":110,"eligibilityCriteria":111,"healthyVolunteers":11,"sex":112,"minAge":18,"maxAge":113,"enrollmentInfo":114,"targetDuration":4,"studyType":23,"phases":116,"briefSummary":117,"conditions":118,"keywords":121,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":125,"lastUpdatePostDateStruct":126,"startDateStruct":128,"completionDateStruct":130,"leadSponsor":132,"locationsCount":47},"100513535","exploratory-evaluation-of-the-effect-of-cholestyramine-on-serum-levels-of-pops-in-obese-female-patients-100513535","NCT05966727","Exploratory Evaluation of the Effect of Cholestyramine on Serum Levels of POPs in Obese Female Patients","Exploratory Evaluation of the Effect of Cholestyramine on Serum Levels of Persistent Organic Pollutants in Obese Female Patients - OBESE (OBesity, CholEStyramine, WomEn)","OBESE","Inclusion Criteria:\n\n* Female patients with a retained indication for bariatric surgery (BMI \\> 40 kg\u002Fm2 or BMI \\> 35 kg\u002Fm2 with complication(s) amenable to improvement by surgery)\n* Aged between 18 and 45\n* Using effective contraception (oral contraception, hormonal or non-hormonal intrauterine device, progestin implant), which will be adapted in the perioperative period in accordance with current recommendations (HAS, BARIA-MAT)\n* Affiliated to a social security scheme\n* Have signed an informed consent form\n\nExclusion Criteria:\n\n* Pregnant (urine pregnancy test) or breast-feeding women\n* Known allergy or intolerance to cholestyramine\n* Chronic constipation\n* Chronic pathology likely to interfere with treatment efficacy (unbalanced diabetes characterized by HbA1c \\> 7%, known and treated dyslipidemia, chronic renal insufficiency with GFR \\\u003C 60 ml\u002Fmin, hepatocellular insufficiency)\n* Patients receiving anti-vitamin K, digoxin or levothyroxine therapy, or likely to receive such therapy within 3 months of inclusion.\n* Phenylketonuria\n* Inability to give consent\n* Patient under legal protection (guardianship, curatorship, safeguard of justice...)\n* Patient deprived of liberty by judicial or administrative decision,\n* Patients under psychiatric care which makes it impossible for them to consent to participation, or who are hospitalized under duress.\n* Participation in another interventional study (outside the PaCO project).","FEMALE","45 Years",{"count":115,"type":22},20,[25],"Environmental endocrine disruptors (EDCs) represent a major problem for human health.Some PEEs can accumulate in the fatty tissue of the human body thanks to their lipophilic nature, and are known as persistent organic pollutants (POPs).\n\nTo assess the benefit of cholestyramine treatment on POPs blood levels in obese patients of childbearing age undergoing bariatric surgery, in order to reduce their preoperative POPs load more rapidly. Indeed, the investigators hypothesize that cholestyramine is capable, outside of acute exposure accidents, of promoting the elimination and release of POPs in the human population. Given this hypothesis, a treatment administered prior to bariatric surgery could reduce pre-operative plasma levels of POPs and thus, in fine, minimize the concentrations reached post-operatively, which are dependent on the release induced by lipolysis (massive and rapid weight loss) and pre-operative plasma concentrations.",[28,119,120],"Diabetes","Bariatric Surgery Candidate",[122,123,119,124],"endocrine disrupter","Obesity","Bariatric Surgery","2025-03-21",{"date":127,"type":39},"2025-03-24",{"date":129,"type":39},"2025-03-19",{"date":131,"type":22},"2026-06-19",{"name":133,"class":46},"Centre Hospitalier Universitaire de Nice",{"id":135,"slug":136,"hasResults":11,"nctId":137,"briefTitle":138,"officialTitle":138,"acronym":139,"eligibilityCriteria":140,"healthyVolunteers":11,"sex":17,"minAge":141,"maxAge":4,"enrollmentInfo":142,"targetDuration":4,"studyType":144,"phases":4,"briefSummary":145,"conditions":146,"keywords":164,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":174,"lastUpdatePostDateStruct":175,"startDateStruct":177,"completionDateStruct":179,"leadSponsor":181,"locationsCount":47},"100569420","osaka-cardiometabolic-epidemiological-study-ohtori-study-part-2-100569420","NCT06694012","Osaka Cardiometabolic Epidemiological Study: Ohtori Study Part 2","OCES-2","Inclusion Criteria:\n\n\\-\n\nExclusion Criteria:\n\n* Women who may be pregnant","20 Years",{"count":143,"type":22},2000,"OBSERVATIONAL","The aim of this study is to investigate the relationship between body fat distribution measured by CT scan and related risk factors with the risk of incident metabolic and cardiovascular disease in a prospective cohort study of Japanese men and women. The investigators will also investigate novel risk factors for metabolic and cardiovascular disease using molecular weight-based metallomics analysis.",[147,148,149,150,151,152,153,154,155,123,156,28,157,158,159,160,161,162,163],"Type 2 Diabetes Mellitus (T2DM)","Type 2 Diabetes","Diabetes Mellitus","Hypertension","Hyperglycemia","Hyperlipidemia","Dyslipidemia","Hyperuricemia or Gout","Hyperuricemia, Gout","Obesity\u002FEpidemiology","Central Obesity","Visceral Fat","Chronic Kidney Disease(CKD)","Atherosclerosis","Metabolic Syndrome","Hepatic Steatosis","Insulin Sensitivity\u002FResistance",[165,150,152,153,166,33,167,168,169,170,171,161,172,173],"Type 2 Diabetes Mellitus","Hyperuricemia","Abdominal obesity","Visceral fat","Visceral adiposity","Chronic Kidney Disease","Japanese","Insulin Sensitivity","Insulin Resistance","2024-11-29",{"date":176,"type":39},"2024-12-04",{"date":178,"type":39},"2024-11-01",{"date":180,"type":22},"2050-03-31",{"name":182,"class":46},"Osaka Metropolitan University"]